thiohydantoins has been researched along with Alzheimer-Disease* in 2 studies
2 other study(ies) available for thiohydantoins and Alzheimer-Disease
Article | Year |
---|---|
Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity.
Recent genetic evidence supports a link between microglia and the complement system in Alzheimer's disease (AD). In this study, we uncovered a novel role for the microglial complement receptor 3 (CR3) in the regulation of soluble β-amyloid (Aβ) clearance independent of phagocytosis. Unexpectedly, ablation of CR3 in human amyloid precursor protein-transgenic mice results in decreased, rather than increased, Aβ accumulation. In line with these findings, cultured microglia lacking CR3 are more efficient than wild-type cells at degrading extracellular Aβ by secreting enzymatic factors, including tissue plasminogen activator. Furthermore, a small molecule modulator of CR3 reduces soluble Aβ levels and Aβ half-life in brain interstitial fluid (ISF), as measured by in vivo microdialysis. These results suggest that CR3 limits Aβ clearance from the ISF, illustrating a novel role for CR3 and microglia in brain Aβ metabolism and defining a potential new therapeutic target in AD. Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Benzoates; Brain; Macrophage-1 Antigen; Mice; Mice, Inbred C57BL; Microglia; Proteolysis; Thiohydantoins | 2017 |
Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains.
A novel series of rhodanin (RH) and thiohydantoin (TH) derivatives were designed and synthesized for detecting tau pathology in the brains of patients with Alzheimer's disease (AD). In experiments in vitro using tau and β-amyloid (Aβ) aggregates, the TH derivative, TH2, showed high specific binding to tau aggregates. In hippocampal sections obtained from AD patients, TH2 intensely stained neurofibrillary tangles. In experiments using normal mice, [(125)I]TH2 showed good uptake (1.54%ID/g, 2 min postinjection) into and a rapid washout (0.25%ID/g, 60 min postinjection) from the brain. [(123)I]TH2 should be further investigated as a potential imaging agent for detecting tau pathology. Topics: Alzheimer Disease; Animals; Autoradiography; Benzothiazoles; Brain; Humans; Iodine Radioisotopes; Mice; Neurofibrillary Tangles; Positron-Emission Tomography; Radiopharmaceuticals; Recombinant Proteins; Rhodanine; Tauopathies; Thiazoles; Thiohydantoins; Tissue Distribution | 2011 |